AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis

RecruitingNAAges 6 Years - 65 YearsAllAssistance Publique Hopitaux De Marseille
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Anorexia nervosa (AN) is a psychiatric disorder belonging to the eating disorders (EDs). It is internationally recognized as a priority for improving health care. Among the markers of severity of undernutrition is hepatic cytolysis. Around 30-50% of patients with AN present with hepatic cytolysis, of variable intensity, and usually associated with severe undernutrition. In a previous study, we demonstrated the presence of autoantibodies against HIF1alpha (Hypoxic inducible Factor 1 alpha) in 22% of cases in a sample of patients with AN. HIF1alpha (HIF1a) is a major transcription factor involved in the regulation of satiety and hunger. These autoantibodies were positive in 80% of AN patients with hepatic cytolysis. Taken together, these data led us to hypothesize an anti-HIF1a autoimmune mechanism in AN, potentially involved in the patients' hepatic cytolysis. This pioneering study, demo

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Experimental group: * Male or female, 6 to 65 years of age * Anorexia nervosa diagnosed according to DSM-5 criteria * Presence of undernutrition according to HAS 2019 criteria * Patient having received information about the study and having signed an informed consent form * Beneficiary or beneficiary of a social security scheme Control group: * Minor patients : * Male or female strictly under 18 years of age * Patients undergoing scheduled non-inflammatory surgery (orthopedic, ENT, etc.) * Patients who have been informed about the study and have signed an informed consent form. * Patients who are beneficiaries or entitled beneficiaries of a social security scheme. * Patients without anorexia with livers cytolysis : * Male or female between 18 and 65 years of age * With hepatic cytolysis determined by an ALT value at least equal to twice the normal value * Patient having received information about the study and having signed an informed consent form * Patient who is a beneficiary or eligible beneficiary of a social security scheme. * samples Etablissement Franรงais de don de sang: no specific criteria Exclusion Criteria: * Patient in a period of exclusion from another research protocol at the time consent is signed. * Opposition of patient and parents or legal guardians * Psychiatric disorder preventing patient consent to study * Person unable to understand the French language * Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women).
๐Ÿ’Š

What it tests

  • blood sampling
  • blood sampling after 3-4 months
๐Ÿ“

Where

1 site
Assistance Publique Hopitaux De Marseille
Marseille, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy